Special Issue "Self-Assembled Nanoparticles: An Emerging Delivery Platform for Drugs"
Deadline for manuscript submissions: 30 November 2023 | Viewed by 3691
Interests: nanoparticle drug delivery; self-assembly of nanoparticles; targeted drug delivery
Most chemical moieties that show therapeutic potential suffer from limitations such as undefined metabolism or unwanted adverse effects. With the discovery of nanotechnology just about a decade ago, remarkable success has been achieved. Due to the small nature of the subunits (10-9 m), nanoparticles often tend to organize in nanostructured self-assemblies. Self-assembly can be defined as a process that causes synergistic interaction between self-organizing particles, leading to a hierarchically ordered structure with the minimal external direction needed. The advantages are myriad; loading of drugs according to morphological requirements can provide versatility, dispersibility in aqueous media can provide stability, the absence of formulation excipients can offer clinical safety and biocompatibility, and the quick and easy fabrication with minimal requirement of special equipment can provide low production cost and ease of manufacturing. These processes have gained the attention of researchers and enabled the development of delivery systems for various applications. Since the first success of nanotechnology with the FDA approval of self-assembled liposomes in 1995 for Doxil®, groundbreaking advancement was made very recently when approved for clinical use of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of self-assembling nanoparticle drug delivery systems is advancing rapidly toward clinical use. Thus, in this framework, the aim of this Special Issue on “Self-Assembled Nanoparticles: An Emerging Delivery Platform for Drugs” is to unify manuscripts that aim to utilize the process of self-assembly to develop nanomaterials for improved drug delivery systems for available drugs. We welcome articles with a particular focus on addressing state-of-the-art knowledge and future perspectives for the application of self-assembly and the emergence of new approaches for the clinical translation of drug delivery.
Dr. Pallabita Chowdhury
Prof. Dr. Xiuling Lu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug delivery developments
- lipid nanoparticles
- polymeric nanoparticles
- therapeutic delivery
- miRNA delivery
- preclinical and clinical translation of drug delivery